Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection

Journal of Hepatology

Volumn 48, Issue 1, 2008, Pages 83-90

  Schmitz, Klaus Juergen ^a   Wohlschlaeger, Jeremias ^a   Lang, Hauke ^a   Sotiropoulos, Georgios Charalambos ^a   Malago, Massimo ^a   Steveling, Karen ^a   Reis, Henning ^a   Cicinnati, Vito Rosario ^a   Schmid, Kurt Werner ^a   Baba, Hideo Andreas ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

AKT; ERK; Hepatocellular carcinoma; Immunohistochemistry; Prognosis

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

ALCOHOL CONSUMPTION; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE FREE SURVIVAL; ENZYME ACTIVATION; ENZYME REGULATION; FEMALE; HEPATITIS B; HEPATITIS C VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NICK END LABELING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

ADULT; ALCOHOLISM; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HEPATECTOMY; HEPATITIS B; HEPATITIS C; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LIVER DISEASES, ALCOHOLIC; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MICROARRAY ANALYSIS; ONCOGENE PROTEIN V-AKT; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 36549013178     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.08.018     Document Type: Article

References (43)

1. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
2. El Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
3. Sebolt-Leopold J.S. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19 (2000) 6594-6599
4. Sebolt-Leopold J.S., and Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4 (2004) 937-947
5. Pearson G., Robinson F., Beers G.T., Xu B.E., Karandikar M., Berman K., et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22 (2001) 153-183
6. Robinson M.J., and Cobb M.H. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9 (1997) 180-186
7. Schaeffer H.J., and Weber M.J. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 19 (1999) 2435-2444
8. Seth A., Gonzalez F.A., Gupta S., Raden D.L., and Davis R.J. Signal transduction within the nucleus by mitogen-activated protein kinase. J Biol Chem 267 (1992) 24796-24804
9. Pulverer B.J., Kyriakis J.M., Avruch J., Nikolakaki E., and Woodgett J.R. Phosphorylation of c-jun mediated by MAP kinases. Nature 353 (1991) 670-674
10. Xiong Y., Connolly T., Futcher B., and Beach D. Human D-type cyclin. Cell 65 (1991) 691-699
11. Ito Y., Sasaki Y., Horimoto M., Wada S., Tanaka Y., Kasahara A., et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27 (1998) 951-958
12. Tsuboi Y., Ichida T., Sugitani S., Genda T., Inayoshi J., Takamura M., et al. Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma. Liver Int 24 (2004) 432-436
13. Wiesenauer C.A., Yip-Schneider M.T., Wang Y., and Schmidt C.M. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. J Am Coll Surg 198 (2004) 410-421
14. Huynh H., Nguyen T.T., Chow K.H., Tan P.H., Soo K.C., and Tran E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 3 (2003) 19
15. Franke T.F., Kaplan D.R., and Cantley L.C. PI3K: downstream AKTion blocks apoptosis. Cell 88 (1997) 435-437
16. Franke T.F. A difficult AKT to follow. Neural Notes 5 (1999) 1
17. Sobin L.H., and Wittekind C. International union against cancer. 6th ed. TNM classification of malignant tumours (2002), Wiley-Liss, New York
18. Schmitz K.J., Wohlschlaeger J., Alakus H., Bohr J., Stauder M.A., Worm K., et al. Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations. Virchows Arch 450 (2007) 151-159
19. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66 (2006) 11851-11858
20. Abou-Alfa G.K., Schwartz L., Ricci S., Amadori D., Santoro A., Figer A., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006) 4293-4300
21. O'Farrell A.M., Foran J.M., Fiedler W., Serve H., Paquette R.L., Cooper M.A., et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9 (2003) 5465-5476
22. Foster J., Black J., Levea C., Khoury T., Kuvshinoff B., Javle M., et al. COX-2 Expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival. Ann Surg Oncol 14 (2007) 752-758
23. Nakanishi K., Sakamoto M., Yamasaki S., Todo S., and Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 103 (2005) 307-312
24. Marais R., Wynne J., and Treisman R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 73 (1993) 381-393
25. Chen R.H., Chung J., and Blenis J. Regulation of pp90rsk phosphorylation and S6 phosphotransferase activity in Swiss 3T3 cells by growth factor-, phorbol ester-, and cyclic AMP-mediated signal transduction. Mol Cell Biol 11 (1991) 1861-1867
26. Chen R.H., Abate C., and Blenis J. Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase. Proc Natl Acad Sci USA 90 (1993) 10952-10956
27. Xing J., Ginty D.D., and Greenberg M.E. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273 (1996) 959-963
28. Torii S., Kusakabe M., Yamamoto T., Maekawa M., and Nishida E. Sef is a spatial regulator for Ras/MAP kinase signaling. Dev Cell 7 (2004) 33-44
29. Schmitz K.J., Otterbach F., Callies R., Levkau B., Holscher M., Hoffmann O., et al. Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol 17 (2004) 15-21
30. Perez-Tenorio G., and Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86 (2002) 540-545
31. Yamamoto S., Tomita Y., Hoshida Y., Morooka T., Nagano H., Dono K., et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 10 (2004) 2846-2850
32. Handra-Luca A., Bilal H., Bertrand J.C., and Fouret P. Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation. Am J Pathol 163 (2003) 957-967
33. Givant-Horwitz V., Davidson B., Lazarovici P., Schaefer E., Nesland J.M., Trope C.G., et al. Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol 91 (2003) 160-172
34. Milde-Langosch K., Bamberger A.M., Rieck G., Grund D., Hemminger G., Muller V., et al. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 92 (2005) 2206-2215
35. Nishida N., Fukuda Y., Komeda T., Kita R., Sando T., Furukawa M., et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 54 (1994) 3107-3110
36. Zhang Y.J., Jiang W., Chen C.J., Lee C.S., Kahn S.M., Santella R.M., et al. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 196 (1993) 1010-1016
37. Li Z., Wang C., Jiao X., Lu Y., Fu M., Quong A.A., et al. Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol Cell Biol 26 (2006) 4240-4256
38. Joo M., Kang Y.K., Kim M.R., Lee H.K., and Jang J.J. Cyclin D1 overexpression in hepatocellular carcinoma. Liver 21 (2001) 89-95
39. Berasain C., Castillo J., Prieto J., and Avila M.A. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int 27 (2007) 174-185
40. Sato Y., Kato J., Takimoto R., Takada K., Kawano Y., Miyanishi K., et al. Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB. Gut 55 (2006) 1801-1808
41. Tsutsumi T., Suzuki T., Moriya K., Shintani Y., Fujie H., Miyoshi H., et al. Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice. Hepatology 38 (2003) 820-828
42. Zhao L.J., Wang L., Ren H., Cao J., Li L., Ke J.S., et al. Hepatitis C virus E2 protein promotes human hepatoma cell proliferation through the MAPK/ERK signaling pathway via cellular receptors. Exp Cell Res 305 (2005) 23-32
43. Saito I., Miyamura T., Ohbayashi A., Harada H., Katayama T., Kikuchi S., et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 87 (1990) 6547-6549